BSI-201 (0703):

Phase I/II Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients with Newly Diagnosed Malignant Glioma.

• Patient Information and Eligibility for Phase I
• Sample Informed Consent for Phase I Group I
• Sample Informed Consent for Phase I Group II

NCCTG N0874 / ABTC 0902:

Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radioation Therapy in Patients with Newly Diagnosed Glioblastoma.

• Patient Information and Eligibility for Phase I
• Sample Informed Consent for Phase II Group I 

Mibefradil (NABTC1101):

A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrant High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.

• Patient Information - Dose Finding
• Patient Information - Dose Expansion
• Eligibility Checklist
• Sample Informed Consent